Amova Asset Management Americas Inc. Cuts Stake in Intellia Therapeutics, Inc. $NTLA

Amova Asset Management Americas Inc. decreased its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 6.9% in the fourth quarter, Holdings Channel.com reports. The firm owned 2,192,461 shares of the company’s stock after selling 162,395 shares during the period. Amova Asset Management Americas Inc.’s holdings in Intellia Therapeutics were worth $19,688,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in the business. Vanguard Group Inc. boosted its stake in shares of Intellia Therapeutics by 17.8% in the 4th quarter. Vanguard Group Inc. now owns 13,010,001 shares of the company’s stock valued at $116,960,000 after purchasing an additional 1,965,181 shares in the last quarter. Contrarius Group Holdings Ltd raised its holdings in Intellia Therapeutics by 279.4% during the 3rd quarter. Contrarius Group Holdings Ltd now owns 5,889,936 shares of the company’s stock valued at $101,719,000 after buying an additional 4,337,428 shares during the last quarter. Baker BROS. Advisors LP raised its holdings in Intellia Therapeutics by 2.7% during the 3rd quarter. Baker BROS. Advisors LP now owns 2,746,674 shares of the company’s stock valued at $47,435,000 after buying an additional 71,000 shares during the last quarter. Geode Capital Management LLC raised its holdings in Intellia Therapeutics by 4.1% during the 4th quarter. Geode Capital Management LLC now owns 2,696,187 shares of the company’s stock valued at $24,243,000 after buying an additional 107,333 shares during the last quarter. Finally, Two Sigma Investments LP raised its holdings in Intellia Therapeutics by 7.6% during the 3rd quarter. Two Sigma Investments LP now owns 2,449,607 shares of the company’s stock valued at $42,305,000 after buying an additional 173,033 shares during the last quarter. Hedge funds and other institutional investors own 88.77% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently commented on NTLA. Wedbush reiterated a “neutral” rating and set a $12.00 price target on shares of Intellia Therapeutics in a report on Tuesday, May 12th. Wells Fargo & Company upped their price target on shares of Intellia Therapeutics from $12.00 to $15.00 and gave the company an “equal weight” rating in a report on Tuesday, March 3rd. Citigroup reiterated an “outperform” rating on shares of Intellia Therapeutics in a report on Tuesday, April 28th. Truist Financial upgraded shares of Intellia Therapeutics to a “strong-buy” rating in a report on Wednesday, March 25th. Finally, HC Wainwright lowered their price target on shares of Intellia Therapeutics from $30.00 to $25.00 and set a “buy” rating for the company in a report on Wednesday, May 13th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, ten have given a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $20.25.

Intellia Therapeutics Trading Down 4.4%

Shares of NASDAQ NTLA opened at $12.89 on Wednesday. Intellia Therapeutics, Inc. has a 12 month low of $7.95 and a 12 month high of $28.25. The firm has a market capitalization of $1.80 billion, a PE ratio of -3.64 and a beta of 1.92. The firm has a fifty day simple moving average of $13.62 and a two-hundred day simple moving average of $12.24.

Intellia Therapeutics (NASDAQ:NTLA) last issued its quarterly earnings data on Monday, May 11th. The company reported ($0.81) EPS for the quarter, topping the consensus estimate of ($0.92) by $0.11. Intellia Therapeutics had a negative net margin of 597.04% and a negative return on equity of 57.47%. The business had revenue of $15.05 million during the quarter, compared to analyst estimates of $13.81 million. During the same period in the prior year, the business earned ($1.10) EPS. On average, sell-side analysts predict that Intellia Therapeutics, Inc. will post -3.23 earnings per share for the current year.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.